Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection.
Clin Microbiol Infect
; 26(9): 1256.e9-1256.e11, 2020 Sep.
Article
in English
| MEDLINE | ID: covidwho-591567
ABSTRACT
OBJECTIVE:
This study aimed to evaluate the diagnostic performance of the Abbott Architect SARS-CoV-2 IgG assay in COVID-19 patients.METHODS:
Residual sera from 177 symptomatic SARS-CoV-2-positive patients and 163 non-COVID-19 patients were tested for antibody with the Abbott SARS-CoV-2 IgG assay (Abbott Diagnostics, Chicago, USA). Clinical records for COVID-19 patients were reviewed to determine the time from onset of clinical illness to testing.RESULTS:
Specificity of the assay was 100.0% (95%CI 97.1-100.0%). The clinical sensitivity of the assay varied depending on time from onset of symptoms, increasing with longer periods from the onset of clinical illness. The clinical sensitivity at ≤6 days was 8.6% (7/81; 95%CI 3.8-17.5%), at 7-13 days 43.6% (17/39; 95%CI 28.2-60.2%), at 14-20 days 84.0% (21/25; 95%CI 63.1-94.7%), and at ≥21 days 84.4% (27/32; 95%CI 66.5-94.1%). Clinical sensitivity was higher in the ≥14-day group compared to <14 days. There were no differences between the 14-20-day and ≥21-days groups; the combined clinical sensitivity for these groups (≥14 days) was 84.2% (49/57; 71.6-92.1%).CONCLUSION:
The Abbott SARS-CoV-2 IgG test has high specificity. Clinical sensitivity was limited in the early stages of disease but improved from 14 days after the onset of clinical symptoms.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoglobulin G
/
COVID-19 Serological Testing
/
COVID-19
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Clin Microbiol Infect
Journal subject:
Communicable Diseases
/
Microbiology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS